Skip to main content

Table 1 Resistance rates for clinical Escherichia coli

From: Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli in Riyadh: emergence of CTX-M-15-producing E. coli ST131

Antimicrobial agents

Number (%) of resistant isolates

ESBL (n = 31)

Non-ESBL (n = 121)

Total (n = 152)

Amoxicillin

31 (100)

121 (100)

152 (100)

Amoxicillin/clavulanic acid

31 (100)

115 (95)

146 (96)

Piperacillin

31 (100)

99 (81.81)

130 (85.52)

Piperacillin/tazobactam

24 (77.44)

52 (42.97)

76 (50)

Cefoxitin

22(70.3)

87 (71.1)

109 (71.7)

Ceftazidime

31 (100)

2 (1.65)

33 (21.71)

Cefotaxime

31 (100)

3 (2.47)

34 (22.36)

Cefepime

31 (100)

2 (1.65)

33 (21.71)

Aztreonam

31 (100)

2 (1.65)

33 (21.71)

Imipenem

0 (0.0)

0 (0.0)

0 (0.0)

Meropenem

0 (0.0)

0 (0.0)

0 (0.0)

Ciprofloxacin

30 (96.77)

49 (40.5)

79 (51.97)

Gentamicin

26 (83.87)

37 (30.58)

63 (41.44)

Amikacin

17 (54.38)

25 (20.66)

42 (27.63)

Colistin

0 (0.0)

0 (0.0)

0 (0.0)

Tigecycline

0 (0.0)

0 (0.0)

0 (0.0)

Fosfomycin

0 (0.0)

0 (0.0)

0 (0.0)